Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 102-107 , 30 October 2009

Antibodies to specific EBNA-1 domains and HLA DRB1⁎1501 interact as risk factors for multiple sclerosis

  • Peter Sundström

      Affiliations

    • Department of Neurology, Umeå University Hospital, SE-901 85 Umeå, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 90 785 19 42; fax: +46 90 13 80 45.
    • ,
  • Maria Nyström

      Affiliations

    • Department of Molecular Biology, Umeå University, SE-901 87 Umeå, Sweden
    • ,
  • Kristina Ruuth

      Affiliations

    • Department of Molecular Biology, Umeå University, SE-901 87 Umeå, Sweden
    • ,
  • Erik Lundgren

      Affiliations

    • Department of Molecular Biology, Umeå University, SE-901 87 Umeå, Sweden

Received 4 May 2009 ,Revised 14 August 2009 ,Accepted 14 August 2009.

References 

  1. Alexander FE, Jarrett RF, Lawrence D, Armstrong AA, Freeland J, Gokhale DA, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br. J. Cancer. 2000;82:1117–1121
  2. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein–Barr virus in pediatric multiple sclerosis. Jama. 2004;291:1875–1879
  3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007;61:288–299
  4. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. Jama. 2001;286:3083–3088
  5. Balandraud N, Meynard JB, Auger I, Sovran H, Mugnier B, Reviron D, et al. Epstein–Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003;48:1223–1228
  6. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein–Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J. Rheumatol. 2000;27:866–873
  7. Bray PF, Luka J, Culp KW, Schlight JP. Antibodies against Epstein–Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology. 1992;42:1798–1804
  8. Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Bussow K, et al. Identification of Epstein–Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 2005;115:1352–1360
  9. De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1⁎1501 and Epstein–Barr virus in multiple sclerosis. Neurology. 2008;70:1113–1118
  10. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 2006;63:839–844
  11. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004;3:104–110
  12. EMBL . Protein Expression and Purification Facility. 2001;
  13. Fox R, Sportsman R, Rhodes G, Luka J, Pearson G, Vaughan J. Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein–Barr virus-encoded associated nuclear antigen. J. Clin. Invest. 1986;77:1539–1547
  14. Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 2007;15:823–830
  15. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 2005;174:6599–6607
  16. Haan KM, Longnecker R. Coreceptor restriction within the HLA-DQ locus for Epstein–Barr virus infection. Proc. Natl. Acad. Sci. U. S. A. 2000;97:9252–9257
  17. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007;357:851–862
  18. Hinderer W, Horn J, Nebel-Schickel H, Vornhagen R, Sonneborn HH, Wolf H. Serodiagnosis of Epstein–Barr virus infection: time for new generation assays provided by recombinant DNA technology. Biotest Bull. 1990;4:141–146
  19. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, et al. Multiple sclerosis and Epstein–Barr virus. Jama. 2003;289:1533–1536
  20. Lunemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Munz C, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006;129:1493–1506
  21. Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J. Exp. Med. 2008;205:1763–1773
  22. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–1104
  23. McAulay KA, Higgins CD, Macsween KF, Lake A, Jarrett RF, Robertson FL, et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J. Clin. Invest. 2007;117:3042–3048
  24. McClain MT, Rapp EC, Harley JB, James JA. Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein–Barr virus nuclear antigen-1. J. Med. Virol. 2003;70:253–257
  25. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 2005;11:85–89
  26. McClain MT, Poole BD, Bruner BF, Kaufman KM, Harley JB, James JA. An altered immune response to Epstein–Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:360–368
  27. Munz C. Epstein–Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J. Exp. Med. 2004;199:1301–1304
  28. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Conner K, Hafler DA, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature. 2007;448:474–479
  29. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  30. Rand KH, Houck H, Denslow ND, Heilman KM. Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1998;65:48–55
  31. Rickinson AB, Kieff E. Epstein–Barr virus. In:  Fields BN,  Knipe DM,  Howley PM, et al. editor. Fields Virology. Philadelphia: Lippincott — Raven Publishers; 1996;
  32. Schmauss C, Lerner MR. The closely related small nuclear ribonucleoprotein polypeptides N and B/B′ are distinguishable by antibodies as well as by differences in their mRNAs and gene structures. J. Biol. Chem. 1990;265:10733–10739
  33. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007;204:2899–2912
  34. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 1998;4:939–944
  35. Sumaya CV, Myers LW, Ellison GW. Epstein–Barr virus antibodies in multiple sclerosis. Arch. Neurol. 1980;37:94–96
  36. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988–97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J. Neurol. Neurosurg. Psychiatry. 2003;74:29–32
  37. Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, et al. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62:2277–2282
  38. Sundstrom P, Nystrom L, Jidell E, Hallmans G. EBNA-1 reactivity and HLA DRB1⁎1501 as statistically independent risk factors for multiple sclerosis: a case–control study. Mult. Scler. 2008;14:1120–1122
  39. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 2006;59:499–503
  40. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature. 1995;375:798–801
  41. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J. Immunol. 1999;162:129–135
  42. Wagner HJ, Munger KL, Ascherio A. Plasma viral load of Epstein–Barr virus and risk of multiple sclerosis. Eur. J. Neurol. 2004;11:833–834

☆ Statistical analysis was carried out by Dr Sundström, Department of Neurology, Umeå University Hospital, Sweden.

PII: S0165-5728(09)00309-9

doi: 10.1016/j.jneuroim.2009.08.004

Journal of Neuroimmunology
Volume 215, Issue 1 , Pages 102-107 , 30 October 2009

Article Tools

* Image Usage & Resolution